NASDAQ:ABCM Abcam (ABCM) Stock Forecast, Price & News $16.90 +0.65 (+4.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$16.31▼$17.0550-Day Range$12.62▼$17.9052-Week Range$12.48▼$18.38Volume1.34 million shsAverage Volume994,829 shsMarket Capitalization$3.87 billionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Abcam MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside36.1% Upside$23.00 Price TargetShort InterestHealthy0.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.26Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth26.83%From $0.41 to $0.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector189th out of 983 stocksBiological Products, Except Diagnostic Industry23rd out of 164 stocks 3.3 Analyst's Opinion Consensus RatingAbcam has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Abcam has a forecasted upside of 36.1% from its current price of $16.90.Amount of Analyst CoverageAbcam has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Abcam have been sold short.Short Interest Ratio / Days to CoverAbcam has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Abcam has recently decreased by 15.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbcam does not currently pay a dividend.Dividend GrowthAbcam does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABCM. Previous Next 2.9 News and Social Media Coverage News SentimentAbcam has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Abcam this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abcam insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.73% of the stock of Abcam is held by insiders.Percentage Held by InstitutionsOnly 13.91% of the stock of Abcam is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Abcam are expected to grow by 26.83% in the coming year, from $0.41 to $0.52 per share.Price to Earnings Growth RatioAbcam has a PEG Ratio of 1.76. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAbcam has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Abcam (NASDAQ:ABCM) StockAbcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.Read More Receive ABCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter. Email Address ABCM Stock News HeadlinesJune 2, 2023 | americanbankingnews.comAbcam (NASDAQ:ABCM) Sees Strong Trading VolumeMay 30, 2023 | finance.yahoo.comJonathan Milner calls Extraordinary General Meeting to restore focus to Abcam on governance, execution, and cost controlJune 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 29, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) Short Interest UpdateMay 13, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) Sees Large Increase in Short InterestMay 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Abcam (ABCM)May 4, 2023 | msn.comAbcam to streamline and consolidate operations in bid to cut costsMay 4, 2023 | finance.yahoo.comAbcam, plc Business UpdateJune 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 4, 2023 | americanbankingnews.comAbcam (NASDAQ:ABCM) Reaches New 12-Month High at $17.76May 1, 2023 | americanbankingnews.comRoyal Bank of Canada Boosts Abcam (NASDAQ:ABCM) Price Target to $23.00April 19, 2023 | americanbankingnews.comAbcam (NASDAQ:ABCM) Sees Unusually-High Trading VolumeApril 18, 2023 | americanbankingnews.comShort Interest in Abcam plc (NASDAQ:ABCM) Declines By 25.4%April 14, 2023 | nasdaq.comAbcam (ABCM) Shares Cross Above 200 DMAMarch 29, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) Sees Significant Growth in Short InterestMarch 28, 2023 | finance.yahoo.comABCAM PLC: Final results for the year ended 31 December 2022March 25, 2023 | americanbankingnews.comAbcam plc Forecasted to Earn FY2023 Earnings of $0.40 Per Share (NASDAQ:ABCM)March 24, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) to Post FY2023 Earnings of $0.45 Per Share, SVB Leerink ForecastsMarch 22, 2023 | americanbankingnews.comAbcam plc (NASDAQ:ABCM) to Post FY2024 Earnings of $0.51 Per Share, William Blair ForecastsMarch 22, 2023 | americanbankingnews.comAbcam plc to Post FY2024 Earnings of $0.51 Per Share, William Blair Forecasts (NASDAQ:ABCM)March 21, 2023 | americanbankingnews.comContrasting Brookline Capital Acquisition (NASDAQ:BCAC) & Abcam (NASDAQ:ABCM)March 10, 2023 | finance.yahoo.comAbcam to Report Full Year Results on Monday, March 20, 2023February 24, 2023 | finance.yahoo.comAbcam plc (ABCM) Stock Historical Prices & Data - Yahoo FinanceDecember 14, 2022 | 247wallst.comFirst Look Analysts Research Calls for Wednesday, December 14November 11, 2022 | finance.yahoo.comABCAM PLC: Result of General Meeting - Shareholders approve AIM DelistingMay 6, 2022 | nasdaq.comAbcam - ADR (Sponsored) Shares Fall 0.6% Below Previous 52-Week Low - Market MoverFebruary 22, 2022 | nasdaq.comAbcam Becomes Oversold (ABCM)See More Headlines ABCM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABCM Company Calendar Today6/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ABCM CUSIPN/A CIK1492074 Webwww.abcam.com Phone44-0-12-2369-6000FaxN/AEmployees1,760Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$23.00 Forecasted Upside/Downside+36.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio41.22 P/E Growth1.76Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio0.93 Sales & Book Value Annual Sales$447.49 million Price / Sales8.66 Cash Flow$0.62 per share Price / Cash Flow27.24 Book Value$3.92 per share Price / Book4.31Miscellaneous Outstanding Shares229,270,000Free Float213,842,000Market Cap$3.87 billion OptionableNot Optionable Beta0.64 Key ExecutivesMr. Alan Thomas Hirzel BS (Age 55)M.B.A., M.S., MBA, MS, CEO & Exec. Director Comp: $1.49MMr. Michael Shaun Baldock B.A. (Age 59)CFO & Director Comp: $1.06MMr. Mark DermodyInterim CIOJames StaveleyVP of Investor RelationsMarc PerkinsGen. Counsel & Company Sec.Emma SceatsSr. VP of Sales, Service & Bus. Devel.Mr. Nick SkinnerSr. VP of HRMr. Mark BushfieldSr. VP of Research & InnovationMs. Kirstie Speck BBusScHead of Consumer InsightsMs. Yvonne ChienSr. VP of Customer ExperienceMore ExecutivesKey CompetitorsGinkgo BioworksNYSE:DNAVir BiotechnologyNASDAQ:VIRDenali TherapeuticsNASDAQ:DNLIHalozyme TherapeuticsNASDAQ:HALOKrystal BiotechNASDAQ:KRYSView All CompetitorsInstitutional OwnershipProShare Advisors LLCBought 14,828 shares on 5/26/2023Ownership: 0.006%Ameriprise Financial Inc.Sold 696,446 shares on 5/22/2023Ownership: 1.883%JPMorgan Chase & Co.Bought 20,000 shares on 5/18/2023Ownership: 0.000%New York State Common Retirement FundBought 5,510 shares on 5/18/2023Ownership: 0.006%Belpointe Asset Management LLCBought 1,075 shares on 5/16/2023Ownership: 0.001%View All Institutional Transactions ABCM Stock - Frequently Asked Questions Should I buy or sell Abcam stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABCM shares. View ABCM analyst ratings or view top-rated stocks. What is Abcam's stock price forecast for 2023? 2 brokers have issued 12 month target prices for Abcam's shares. Their ABCM share price forecasts range from $23.00 to $23.00. On average, they predict the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts. How have ABCM shares performed in 2023? Abcam's stock was trading at $15.56 at the beginning of 2023. Since then, ABCM shares have increased by 8.6% and is now trading at $16.90. View the best growth stocks for 2023 here. Are investors shorting Abcam? Abcam saw a decrease in short interest in May. As of May 15th, there was short interest totaling 603,500 shares, a decrease of 15.2% from the April 30th total of 711,400 shares. Based on an average daily trading volume, of 731,700 shares, the short-interest ratio is currently 0.8 days. View Abcam's Short Interest. What ETFs hold Abcam's stock? ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include BlackRock Future Health ETF (BMED), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB), What guidance has Abcam issued on next quarter's earnings? Abcam updated its first quarter 2023 earnings guidance on Monday, April, 17th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $121.46 million-$121.46 million. When did Abcam IPO? (ABCM) raised $149 million in an initial public offering (IPO) on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO. What is Abcam's stock symbol? Abcam trades on the NASDAQ under the ticker symbol "ABCM." Who are Abcam's major shareholders? Abcam's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (6.76%), Wellington Management Group LLP (6.39%), Harding Loevner LP (5.99%), Baillie Gifford & Co. (5.20%), Brown Capital Management LLC (4.25%) and Wasatch Advisors LP (3.55%). How do I buy shares of Abcam? Shares of ABCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Abcam's stock price today? One share of ABCM stock can currently be purchased for approximately $16.90. How much money does Abcam make? Abcam (NASDAQ:ABCM) has a market capitalization of $3.87 billion and generates $447.49 million in revenue each year. How many employees does Abcam have? The company employs 1,760 workers across the globe. How can I contact Abcam? The official website for the company is www.abcam.com. The company can be reached via phone at 44-0-12-2369-6000 or via email at investor.relations@abcam.com. This page (NASDAQ:ABCM) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abcam plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.